Achieving Objective Response in Treatment of Non-Resectable Neuroendocrine Tumors Does Not Predict Longer Time to Progression Compared to Achieving Stable Disease
Introduction: There are several treatment modalities for unresectable neuroendocrine tumors. Traditionally the goal of these treatments are to reduce the tumor load; objective response (OR). Less emphasis has been put on inducing the tumors to stop growing without reduction in total tumor load; stable disease (SD).
Aim(s): We wanted to investigate whether achieving OR compared to achieve SD predicted a longer time to progression in patients with neuroendocrine tumors (WHO Grade 1 and 2) treated with peptide receptor radionuclide therapy, chemotherapy or molecular targeted therapy.
Materials and methods: Patients treated with either PRRT (177Lutetium-DOTA-octreotate), the chemotherapy combination streptozotocin/5-flurouracil or everolimus were retrospectively assessed to register the effect of these treatments on disease progression. We compared the time to progression (TTP) within each treatment modality between those who achieved OR and those who achieved SD.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Thiis-Evensen E
To read the full abstract, please log into your ENETS Member account.